<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02356302</url>
  </required_header>
  <id_info>
    <org_study_id>MTN-027</org_study_id>
    <secondary_id>12014</secondary_id>
    <nct_id>NCT02356302</nct_id>
  </id_info>
  <brief_title>Safety and Pharmacokinetics of Intravaginal Rings Containing Vicriviroc (MK-4176) and/or MK-2048</brief_title>
  <official_title>Phase 1 Safety and Pharmacokinetics Study of MK-2048/Vicriviroc (MK-4176)/MK-2048A Intravaginal Rings</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institute of Allergy and Infectious Diseases (NIAID)</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Research is currently underway to develop new HIV prevention strategies. Intravaginal rings
      (IVRs) are one drug delivery method that is currently being studied. This study will evaluate
      the safety and pharmacokinetics of IVRs containing vicriviroc, MK-2048, and a combination of
      vicriviroc/MK-2048, in healthy, HIV-uninfected women.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The development of safe and effective HIV prevention strategies is an important global health
      priority. IVRs have previously been approved as a delivery method for various medications,
      and this study will evaluate IVRs containing HIV antiretroviral medications. The purpose of
      this study is to assess the safety and pharmacokinetics of a combination IVR called MK-2048A
      that contains vicriviroc (MK-4176) and MK-2048, compared to IVRs containing vicriviroc alone
      and MK-2048 alone.

      This study will enroll healthy, HIV-uninfected women, 18 to 45 years old. Participants will
      be randomly assigned to receive an IVR containing either vicriviroc, MK-2048, MK-2048A (which
      contains vicriviroc and MK-2048), or placebo. Participants will receive their assigned IVR at
      the enrollment visit, and the IVR will be removed on Day 28. Participants will attend study
      visits at screening, enrollment (Day 0), and Days 1, 2, 3, 7, 14, 21, 28, 29, 30, 31, and 35.
      Study visits may include behavioral assessments, adherence counseling and assessments,
      medical history reviews, physical examinations, urine collection, blood collection, pelvic
      specimen collection, and rectal specimen collection (optional).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2015</start_date>
  <completion_date type="Actual">March 2016</completion_date>
  <primary_completion_date type="Actual">March 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of women in each of the four IVR regimens with genitourinary events Grade 1 or higher judged to be related to study product</measure>
    <time_frame>Measured through Day 35</time_frame>
    <description>As defined by the Division of AIDS (DAIDS) Table for Grading the Severity of Adult and Pediatric Adverse Events, Version 1.0, Dec 2004 (Clarification dated August 2009), Addendum 1, (Female Genital Grading Table for Use in Microbicide Studies)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of women in each of the four IVR regimens with adverse events Grade 2 or higher</measure>
    <time_frame>Measured through Day 35</time_frame>
    <description>As defined by the Division of AIDS (DAIDS) Table for Grading the Severity of Adult and Pediatric Adverse Events, Version 1.0, Dec 2004 (Clarification dated August 2009)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Measurement of local and systemic concentrations of vicriviroc (MK-4176)</measure>
    <time_frame>Measured through Day 35</time_frame>
    <description>In plasma, vaginal fluids, and cervical tissue during and after 28 days of continuous use of an IVR containing 182 mg vicriviroc (MK-4176), or 30 mg MK-2048, or 182 mg vicriviroc (MK-4176) + 30 mg MK-2048 (MK-2048A)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Measurement of local and systemic concentrations of MK-2048</measure>
    <time_frame>Measured through Day 35</time_frame>
    <description>In plasma, vaginal fluids, and cervical tissue during and after 28 days of continuous use of an IVR containing 182 mg vicriviroc (MK-4176), or 30 mg MK-2048, or 182 mg vicriviroc (MK-4176) + 30 mg MK-2048 (MK-2048A)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Participant report of acceptability</measure>
    <time_frame>Measured through Day 35</time_frame>
    <description>Including genitourinary and emotional (dis)comfort, awareness/feeling during daily activities, ring insertion/removal issues, and willingness to use in the future</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Participant report of frequency of study IVR removal/expulsion and duration without IVR inserted in vagina</measure>
    <time_frame>Measured through Day 35</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">48</enrollment>
  <condition>HIV Infections</condition>
  <arm_group>
    <arm_group_label>Vicriviroc (MK-4176) Intravaginal Ring (IVR)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The vicriviroc (MK-4176) IVR will be inserted during the enrollment visit (Day 0), and it will be removed on Day 28.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MK-2048 IVR</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The MK-2048 IVR will be inserted during the enrollment visit (Day 0), and it will be removed on Day 28.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MK-2048A IVR</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The MK-2048A IVR will be inserted during the enrollment visit (Day 0), and it will be removed on Day 28.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo IVR</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>The placebo IVR will be inserted during the enrollment visit (Day 0), and it will be removed on Day 28.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Vicriviroc (MK-4176) Intravaginal Ring (IVR)</intervention_name>
    <description>Contains 182 mg vicriviroc (MK-4176).</description>
    <arm_group_label>Vicriviroc (MK-4176) Intravaginal Ring (IVR)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>MK-2048 IVR</intervention_name>
    <description>Contains 30 mg MK-2048.</description>
    <arm_group_label>MK-2048 IVR</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>MK-2048A IVR</intervention_name>
    <description>Contains 182 mg vicriviroc (MK-4176) and 30 mg MK-2048.</description>
    <arm_group_label>MK-2048A IVR</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Placebo IVR</intervention_name>
    <arm_group_label>Placebo IVR</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Born female. Note: Participants who were female at birth, who now identify as male,
             will not be excluded so long as they are not on female-to-male transition therapy.

          -  Age 18 through 45 years (inclusive) at Screening, verified per site SOPs

          -  Able and willing to provide written informed consent to be screened for and take part
             in this study (MTN-027)

          -  Able and willing to provide adequate locator information, as defined by the site SOPs

          -  HIV-uninfected, based on testing performed by study staff at Screening and Enrollment
             (per applicable algorithm in Appendix II of the protocol) and willing to receive
             results

          -  In general good health at Screening and Enrollment, as determined by the site
             Investigator of Record (IoR) or designee

          -  At Screening, participant states willingness to abstain from receptive sexual activity
             (including penile-vaginal intercourse, anal intercourse, receptive oral intercourse,
             finger stimulation, and the use of sex toys) for the 5 days prior to the Enrollment
             Visit and for the duration of study participation

          -  Per participant report, using an effective method of contraception at Enrollment, and
             intending to continue the use of an effective method for the duration of study
             participation. Effective methods for MTN-027 include: hormonal methods (except
             contraceptive IVRs), intrauterine device (IUD) inserted at least 28 days prior to
             enrollment, engages in sex exclusively with women, sterilized (self or partner),
             and/or sexually abstinent for the past 90 days.

          -  Women over the age of 21 (inclusive) must have documentation of a satisfactory Pap
             within the past 3 years prior to Enrollment consistent with Grade 0 according to the
             Female Genital Grading Table for Use in Microbicide Studies Addendum 1 to the DAIDS
             Table for Grading Adult and Pediatric Adverse Events, Version 1.0, December 2004
             (Clarification dated August 2009), or satisfactory evaluation with no treatment
             required of Grade 1 or higher Pap result

          -  Per participant report at Screening and Enrollment, agrees not to participate in other
             research studies involving drugs, medical devices, or vaginal products for the
             duration of study participation

          -  Per participant report at Screening, regular menstrual cycles with at least 21 days
             between menses. Note: This criterion is not applicable to participants who report
             using a progestin-only method of contraception at Screening, e.g., Depo-Provera or
             levonorgestrel-releasing IUD nor to participants using continuous combination oral
             contraceptive pills, as the absence of regular menstrual cycles is an expected, normal
             consequence in this context.

          -  At Screening, participant states a willingness to refrain from inserting any non-study
             vaginal products or objects into the vagina, including, but not limited to,
             spermicides, female condoms, diaphragms, contraceptive IVRs, vaginal medications,
             menstrual cups, cervical caps (or any other vaginal barrier method), douches,
             lubricants, sex toys (vibrators, dildos, etc.) for the 5 days prior to Enrollment and
             for the duration of their study participation

        Exclusion Criteria:

          -  Participant report of any of the following at Screening and/or Enrollment:

               -  History of adverse reactions to any of the components of the study products

               -  Non-therapeutic injection drug use in the 12 months prior to Screening and
                  Enrollment

               -  Post-exposure prophylaxis (PEP) for HIV exposure within 6 months prior to
                  Enrollment

               -  Pre-exposure prophylaxis (PrEP) for HIV prevention within the 6 months prior to
                  Enrollment

               -  Regular use and/or anticipated regular use during the period of study
                  participation of CYP3A inducer(s) and/or inhibitor(s)

               -  Use and/or anticipated use during the period of study participation of
                  female-to-male transition therapy

               -  Chronic and/or recurrent candidiasis

               -  Gonorrhea, chlamydia, and/or syphilis diagnosis in the 6 months prior to
                  Enrollment

               -  Last pregnancy outcome 90 days or less prior to Screening

               -  Currently breastfeeding

               -  Has had a hysterectomy

               -  Intends to become pregnant within the next 3 months

               -  Has plans to relocate away from the study site area in the next 3 months

               -  Current sexual partner is known to be HIV-positive

          -  Reports participating in any other research study involving drugs, medical devices, or
             vaginal products within 60 days or less prior to enrollment

          -  At Screening or Enrollment, as determined by the IoR/designee, any significant
             uncontrolled active or chronic cardiovascular, renal, liver, hematologic, neurologic,
             gastrointestinal, psychiatric, endocrine, respiratory, immunologic disorder or
             infectious disease

          -  Has any of the following laboratory abnormalities at Screening:

               -  Aspartate aminotransferase (AST) or alanine transaminase (ALT) Grade 1 or higher

               -  Calculated creatinine clearance less than 60 mL/min by the Cockcroft-Gault
                  formula, where creatinine clearance (female) in mL/min = (140 - age in years) x
                  (weight in kg) x (0.85)/72 x (creatinine in mg/dL)

               -  Hemoglobin Grade 1 or higher

               -  Platelet count Grade 1 or higher

               -  White blood count Grade 2 or higher

               -  Positive HBsAg test result

               -  Positive anti-hepatitis C virus (HCV) test result

               -  International normalized ratio (INR) greater than 1.5 Ã— the site laboratory upper
                  limit of normal (ULN)

               -  Note: Otherwise eligible participants with an exclusionary test result (other
                  than HIV, hepatitis B virus [HBV], or HCV) can be re-tested during the screening
                  process. If a participant is re-tested and a non-exclusionary result is
                  documented within 45 days of providing informed consent for screening, the
                  participant may be enrolled.

          -  Pregnant at either Screening or Enrollment. Note: A documented negative pregnancy test
             performed by study staff is required for inclusion; however a self-reported pregnancy
             is adequate for exclusion from screening/enrollment into the study.

          -  Diagnosed with urinary tract infection (UTI) at Screening or Enrollment. Note:
             Otherwise eligible participants diagnosed with UTI during screening will be offered
             treatment. If within the 45 day screening window treatment is complete and symptoms
             have resolved the participant may be enrolled.

          -  Diagnosed with pelvic inflammatory disease, reproductive tract infection (RTI) or a
             sexually transmitted infection (STI) requiring treatment per current Centers for
             Disease Control and Prevention (CDC) guidelines (http://www.cdc.gov/std/treatment/) at
             Screening or Enrollment. Note: With the exception of gonorrhea, chlamydia, and/or
             syphilis, otherwise eligible participants diagnosed with a RTI during screening will
             be offered treatment. If within the 45 day screening window treatment is complete and
             symptoms have resolved the participant may be enrolled.

          -  At Enrollment, has a clinically apparent Grade 1 or higher pelvic exam finding
             (observed by study clinician or designee) per the Division of AIDS Table for Grading
             the Severity of Adult and Pediatric Adverse Events, Version 1.0, December 2004
             (Clarification dated August 2009), Addendum 1, Female Genital Grading Table for Use in
             Microbicide Studies. Note: Cervical friability bleeding associated with speculum
             insertion and/or specimen collection judged to be within the range of normal according
             to the clinical judgment of the IoR/designee is considered expected non-menstrual
             bleeding and is not exclusionary.

          -  At Screening, severe pelvic relaxation such that either the vaginal walls or the
             uterine cervix descend beyond the vaginal introitus with valsalva maneuver or has
             pelvic anatomy that compromises the ability to adequately assess vaginal safety

          -  Has any other condition that, in the opinion of the IoR/designee, would preclude
             informed consent, make study participation unsafe, complicate interpretation of study
             outcome data, or otherwise interfere with achieving study objectives
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Craig Hoesley, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University of Alabama at Birmingham</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Alabama CRS</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh CRS</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 2, 2015</study_first_submitted>
  <study_first_submitted_qc>February 4, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 5, 2015</study_first_posted>
  <last_update_submitted>March 15, 2016</last_update_submitted>
  <last_update_submitted_qc>March 15, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 17, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

